

NATIONAL INSTITUTE FOR HEALTH AND CARE EXCELLENCE

Single Technology Appraisal (STA)

Ruxolitinib for treating polycythaemia vera (review of TA356) [ID5106]

Draft stakeholder list of consultees and commentators

Consultees	Commentators (no right to submit or appeal)
<p><u>Company</u></p> <ul style="list-style-type: none"> • Novartis (ruxolitinib) <p><u>Patient/carer groups</u></p> <ul style="list-style-type: none"> • African Caribbean Leukaemia Trust • Anthony Nolan • DKMS • Cancer Black Care • Cancer Equality • Helen Rollason Cancer Charity • Independent Cancer Patients Voice • Macmillan Cancer Support • Maggie's Centres • Marie Curie • Tenovus Cancer Care • Blood Cancer UK • Genetic Alliance UK • Leukaemia Cancer Society • Leukaemia CARE • MPN Voice • South Asian Health Foundation • Specialised Healthcare Alliance <p><u>Professional groups</u></p> <ul style="list-style-type: none"> • British Committee for Standards in Haematology • British Geriatrics Society • British Society for Haematology • Immunodeficiency UK • Royal College of General Practitioners • Royal College of Nursing • Royal College of Pathologists • Royal College of Physicians • Royal Pharmaceutical Society • Royal Society of Medicine • UK Clinical Pharmacy Association • UK Forum on Haemoglobin Disorders <p><u>Others</u></p>	<p><u>General</u></p> <ul style="list-style-type: none"> • All Wales Therapeutics and Toxicology Centre • Allied Health Professionals Federation • Board of Community Health Councils in Wales • British National Formulary • Care Quality Commission • Department of Health, Social Services and Public Safety for Northern Ireland • Healthcare Improvement Scotland • Hospital Information Services - Jehovah's Witnesses • Medicines and Healthcare products Regulatory Agency • National Association of Primary Care • National Pharmacy Association • NHS Alliance • NHS Confederation • Scottish Medicines Consortium • Welsh Health Specialised Services Committee <p><u>Comparator manufacturers</u></p> <ul style="list-style-type: none"> • Aspen Pharma Trading (busulfan) • Aspire Pharma (peginterferon alfa-2a) • Aurobindo Pharma-Milpharm (anagrelide) • Bristol-Myers Squibb (hydroxycarbamide) • Dr Reddy's Laboratories (anagrelide) • Glenmark Pharmaceuticals (anagrelide) • Kent Pharma (anagrelide) • Medac (hydroxycarbamide) • Mylan (anagrelide) • Sandoz (anagrelide) • Takeda UK (anagrelide) • Zentiva (anagrelide)

Draft stakeholder list for the single technology appraisal of ruxolitinib for treating polycythaemia vera (review of TA356) [ID5106]

Issue date: June 2022

<ul style="list-style-type: none"> • Department of Health and Social Care • NHS Bath and North East Somerset CCG • NHS England • NHS Wiltshire CCG • Welsh Government 	<p><u>Relevant research groups</u></p> <ul style="list-style-type: none"> • Cochrane Haematological Malignancies Group • Cochrane UK • Genomics England • MRC Clinical Trials Unit • National Institute for Health Research <p><u>Associated Public Health Groups</u></p> <ul style="list-style-type: none"> • Public Health Wales • UK Health Security Agency
--	---

NICE is committed to promoting equality, eliminating unlawful discrimination and fostering good relations between people who share a protected characteristic and those who do not. Please let us know if we have missed any important organisations from the lists in the stakeholder list, and which organisations we should include that have a particular focus on relevant equality issues.

Definitions:

Consultees

Organisations that accept an invitation to participate in the appraisal; the company that markets the technology; national professional organisations; national patient organisations; the Department of Health and Social Care and the Welsh Government and relevant NHS organisations in England.

The company that markets the technology is invited to make an evidence submission, respond to consultations, nominate clinical experts and has the right to appeal against the final draft guidance (FDG).

All non-company consultees are invited to submit a statement¹, respond to consultations, nominate clinical or patient experts and have the right to appeal against the final draft guidance.

Commentators

Organisations that engage in the appraisal process but that are not asked to prepare an evidence submission or statement, are able to respond to consultations and they receive the FDG for information only, without right of appeal. These organisations are companies that market comparator technologies; Healthcare Improvement Scotland; related research groups where appropriate (for example, the Medical Research Council [MRC], National Cancer Research Institute); other groups (for example, the NHS Confederation, NHS Alliance, and the British National Formulary).

All non-company commentators are invited to nominate clinical or patient experts.

¹ Non company consultees are invited to submit statements relevant to the group they are representing.

